Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
cervical cancer
Pharma
Merck's Keytruda turns in mixed results in gynecological cancers
The company unveiled new data from separate studies in late stage cervical cancer and newly diagnosed endometrial cancer.
Zoey Becker
Sep 13, 2024 6:05pm
Merck's Keytruda improves survival in cervical cancer trial
Mar 15, 2024 11:31am
Merck's Keytruda once again bags imperfect cervical cancer nod
Jan 16, 2024 11:00am
Improve education to boost cervical cancer screening: survey
Jan 15, 2024 7:50am
Merck's Keytruda mostly won out at ESMO, with one notable miss
Oct 24, 2023 9:05am
ESMO: Seagen, Genmab's Tivdak excel in cervical cancer study
Oct 22, 2023 10:30am
